Introduction
============

Asthma, also known as bronchial asthma, refers to chronic airway inflammation involving a variety of cells and cell components. This inflammation often causes an increase in airway response, which can cause repeated attacks of wheezing, shortness of breath, chest distress, cough and other symptoms ([@b1-etm-0-0-8414]). Asthma is a very common chronic respiratory disease at present, with a high morbidity in all ages ([@b2-etm-0-0-8414]). According to statistics, the morbidity of asthma worldwide is approximately 3.8/1,000 ([@b3-etm-0-0-8414]). Previous studies have confirmed that the pathogenic factors of asthma are complex, factors like heredity, inhalation allergen, air pollution and respiratory virus infection all may cause asthma ([@b4-etm-0-0-8414]). Asthma can cause respiratory failure, respiratory arrest, pneumothorax or mediastinal emphysema, and lung infection, and more serious cases will directly cause sudden death ([@b5-etm-0-0-8414]). Ebmeier *et al* ([@b6-etm-0-0-8414]) further indicated that the mortality caused by asthma was on the rise. At present, the diagnosis and treatment of asthma are complicated and difficult. In clinical practice, multiple comprehensive tests such as blood routine, sputum, lung function, blood gas, imaging technology and allergen are required to achieve the purpose of diagnosis, while treatment requires multi-functional treatment and extremely long treatment period, and the complete cure rate is relatively low ([@b7-etm-0-0-8414],[@b8-etm-0-0-8414]). Therefore, in order to effectively control the clinical harm of asthma, researchers are constantly working to explore and find new and effective diagnosis and treatment programs.

With the deepening of research, the application of long-chain non-coding RNA (lncRNA) has gradually become a hot spot ([@b9-etm-0-0-8414]--[@b11-etm-0-0-8414]). As a tumor suppressor, lncRNA *MEG3* has been proved to play a role in a number of tumor diseases ([@b12-etm-0-0-8414],[@b13-etm-0-0-8414]), and Devadoss *et al* ([@b14-etm-0-0-8414]) explained the importance of *MEG3* in chronic obstructive pulmonary disease. However, there is no study that has yet confirmed the effect of *MEG3* on asthma. Because chronic obstructive pulmonary disease was consistent with some pathogenic mechanisms of asthma, we speculated that *MEG3* also had special expression in asthma. In order to verify our conjecture, this experiment provided reference and guidance for future clinical diagnosis and treatment of asthma by exploring and analyzing the expression of *MEG3* in asthma patients and the situation of *MEG3* in asthma with different inflammatory phenotypes.

Materials and methods
=====================

### General information

A total of 119 asthma patients admitted to Wuhan No. 1 Hospital (Wuhan, China) from March 2017 to March 2019 and 125 healthy people undergoing physical examination at the same time were selected as the research objects for prospective analysis.

This experiment was approved by the Ethics Committee of Wuhan No. 1 Hospital. Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians.

### Inclusion and exclusion criteria

Inclusion criteria were as follows: Those in compliance with clinical manifestations of asthma; people who were diagnosed as asthma after a series of examinations in Wuhan No. 1 Hospital; those who had complete case data; those who agreed to cooperate and participate in the investigation of medical staff in Wuhan No. 1 Hospital; those who were 10--70 years old.

Exclusion criteria were as follows: Patients with other respiratory and lung diseases; patients with tumor; patients with autoimmune deficiency diseases; patients with systemic infection; patients with organ dysfunction; patients with other cardiovascular and cerebrovascular diseases; patients with drug allergy; patients with low treatment compliance for mental disorders; patients transferred to another hospital and patients with physical disabilities who could not take care of themselves.

### Methods

Altogether 5 ml of fasting venous blood from the two groups was drawn respectively into EDTA anticoagulants, left at room temperature for 30 min and centrifuged at 800 × g for 10 min to obtain upper serum, which was stored in a refrigerator at −80°C for testing. PCR method was used to detect the expression of *MEG3* in serum of patients. The collected serum was extracted with TRIzol kit (kit and corollary reagents were from Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the extracted total RNA was detected by ultraviolet spectrophotometer and agarose gel electrophoresis for purity, concentration and integrity of total RNA. TransScript^®^ miRNA RT Enzyme Mix and 2X TS miRNA Reaction Mix were used to reverse transcription with total RNA, and the operation steps were strictly in accordance with the manufacturer\'s kit. Then PrimeScript RT Master Mix kit (kit and corollary reagents were from Takara Bio, Inc., Otsu, Japan) was used for PCR amplication experiment. PCR reaction system was as follows: cDNA 1 µl, upstream and downstream primers 0.4 µl each ([Table I](#tI-etm-0-0-8414){ref-type="table"}), 2X TransTaq^®^ Tip Green qPCR SuperMix 10 µl, Passive Reference Dye (50X) 0.4 µl, finally ddH~2~O supplemented to 20 µl. PCR reaction conditions were as follows: pre-denaturation at 94°C for 30 sec, denaturation at 94°C for 5 sec, annealing at 60°C for 30 sec, with a total of 40 cycles. Each sample was provided with 3 repeated wells, and the experiment was carried out 3 times. GAPDH was used as internal reference and 2^−∆Cq^ was used for data analysis ([@b14-etm-0-0-8414]).

### Observation indicators

Expression of *MEG3* in two groups, the predictive value of *MEG3* for asthma, and expression of *MEG3* in asthma with different inflammatory phenotypes were observed. Patients in the research group were followed up for 3 months to record the recurrence of asthma and analyze the risk factors affecting it.

### Statistical analysis

SPSS24.0 (IBM Corp., Armonk, NY, USA) was used to process and analyze all data, and GraphPad 8 was used to draw all graphical results. The counting data were expressed in the form of (rate), and Chi-square test was used for comparison between groups. The measurement data were expressed in the form of (mean ± standard deviation), and the comparison between groups adopted t-test. One-way analysis of variance and LSD back testing were used for comparison among groups, and ROC curve was used to analyze the predicted value. Pearson\'s correlation coefficient was used for correlation analysis, and logistic regression analysis was used to analyze the risk factors. P-value \<0.050 was considered statistically significant.

Results
=======

### Comparison of general information

Age, BMI, sex, smoking, living environment and nationality of the two groups were compared, there was no significant difference (P\>0.050), while there was significant difference between the two groups in family medical history and history of respiratory disease (P\<0.001) ([Table II](#tII-etm-0-0-8414){ref-type="table"}).

### Comparison of the expression level of MEG3

The expression level of *MEG3* in the research group was significantly lower than that in the control group (P\<0.001), and ROC curve analysis showed that when cut-off value was 4.295, the predictive sensitivity, specificity, AUC and 95% CI for detection of *MEG3* were 79.83%, 66.40%, 0.783 and 0.725--0.840, respectively (P\<0.001) ([Fig. 1](#f1-etm-0-0-8414){ref-type="fig"}).

### Expression of MEG3 in different inflammatory phenotypes

The expression level of *MEG3* in patients with mixed granulocytic asthma was the lowest, followed by neutrophilic asthma and eosinophilic asthma, and the expression level of *MEG3* in paucigranulocytic asthma was the highest (P\<0.050) ([Fig. 2](#f2-etm-0-0-8414){ref-type="fig"}).

### Correlation analysis between MEG3 and course of disease

Pearson correlation coefficient analysis showed that the expression level of *MEG3* in the research group was negatively correlated with the course of disease (r=−0.666, P\<0.001) ([Fig. 3](#f3-etm-0-0-8414){ref-type="fig"}).

### Univariate analysis of factors affecting recurrence of asthma

A total of 119 patients in the research group were successfully followed up for 3 months, with a follow-up success rate of 100.0%. Among them, 42 patients who had recurrence of asthma were regarded as recurrence group and the other 77 patients who did not recur were treated as non-recurrence group. Univariate analysis showed that age, BMI, sex, family medical history and nationality were not the single factors affecting recurrence of asthma (P\>0.050), while course of disease, smoking, living environment, history of respiratory, working (learning) environment, inflammatory phenotype and *MEG3* were the single factors affecting recurrence of asthma (P\<0.050) ([Table III](#tIII-etm-0-0-8414){ref-type="table"}).

### Multivariate analysis of factors affecting recurrence of asthma

The indicators with differences in univariate analysis were included in the assignment ([Table IV](#tIV-etm-0-0-8414){ref-type="table"}), and the results were input into SPSS and then selected to go forward: LR was used for logistic regression analysis, and the results revealed that the living environment, history of respiratory disease and working (learning) environment were not independent factors influencing recurrence of asthma (P\>0.050), while the course of disease and inflammatory phenotype were independent risk factors influencing recurrence of asthma (P\<0.050), and *MEG3* was independent protective factor influencing recurrence of asthma (P\<0.050) ([Table V](#tV-etm-0-0-8414){ref-type="table"}).

Discussion
==========

Asthma is airway inflammation involving T lymphocytes, mast cells and other inflammatory mediator cells, which is mainly manifested by symptoms such as wheezing, cough and dyspnea ([@b15-etm-0-0-8414]). Asthma is a respiratory disease caused by the combination of internal and external environment of the body ([@b16-etm-0-0-8414]). The degree of air turbidity and inhaled particles in the external environment are the keys to asthma ([@b17-etm-0-0-8414]), while lncRNA may play a crucial role in the internal environment of the body. lncRNA is a kind of RNA molecule with transcripts over 200nt in length and no protein coding, and it can exert its biological function through a variety of mechanisms ([@b18-etm-0-0-8414]). *MEG3* has been proved to normally play an anti-cancer role in tumor diseases ([@b19-etm-0-0-8414]), but its role in asthma is not yet clear. Facing the increasingly serious asthma diseases, it is of great significance for us to study the situation of *MEG3* in asthma for its clinical diagnosis and treatment in the future.

The results of this experiment showed that *MEG3* was low expressed in asthma patients, suggesting that *MEG3* might be involved in the occurrence of asthma. Zhou *et al* ([@b20-etm-0-0-8414]) also stated that *MEG3* was also low expressed in bronchial epithelial cells, which could support our experimental results. Therefore, we speculated that the role of *MEG3* in asthma might be similar to that of tumor suppressor genes. Some studies claimed that *MEG3* inhibited cell growth, reduced protein synthesis of cells, and down-regulated apoptosis-related protein Bcl-xl to accelerate apoptosis through P13K/m-TOR signaling pathway ([@b21-etm-0-0-8414]). However, Wang *et al* ([@b22-etm-0-0-8414]) indicated that FIZZ1 was the key to cause asthma through airway P13K/Akt signaling, and Zhang *et al* ([@b23-etm-0-0-8414]) studied that P13K and Notch signaling pathway were the keys to regulate activation and proliferation of T lymphocytes in asthma patients. Zhang *et al* ([@b24-etm-0-0-8414]) confirmed that the onset of asthma required activation of the m-TOR signaling pathway. Based on the above, we suspected that the role of *MEG3* in asthma might also be carried out through P13K/m-TOR signaling pathway. However, due to the failure to carry out basic experiments, we still could not verify our hypothesis, and this would also be a focus of our future research for further analysis. Furthermore, we analyzed the predictive value of *MEG3* for asthma, and the results showed that when cut-off value was 4.295, the predictive sensitivity and specificity of *MEG3* for asthma were 79.83 and 66.40%, respectively. It indicated that *MEG3* could be used as an auxiliary diagnostic indicator for asthma in the future and could be used for early screening clinically. Compared with the traditional detection of asthma (such as sputum smear, imaging and analysis of blood gas) ([@b25-etm-0-0-8414]), the advantage of detecting *MEG3* in serum lies in the convenient acquisition of detection samples. Peripheral blood, as the most convenient and minimally invasive detection sample in clinical detection, has a longer preservation period and is conducive to clinical follow-up at any time. However, results of serum test are more objective than imaging results and do not need to rely on the subjective judgment of clinicians for prediction, which also reduces mis-diagnosis and missed diagnosis caused by human factors to a certain extent. However, by comparing the expression level of *MEG3* in asthma with different inflammatory phenotypes, it could be seen that the expression level of *MEG3* was the lowest in patients with mixed granulocytic asthma and the highest in patients with paucigranulocytic asthma, which was basically consistent with the pathological condition of eliminating inflammatory phenotypes ([@b26-etm-0-0-8414]). Mixed granulocytic asthma is the most serious type of asthma, which is characterized by recurrent attacks and refractory treatment, while paucigranulocytic asthma is a well-controlled or intermittent dyspnea. Such patients usually have a short course of disease and a mild condition, and can basically recover after treatment ([@b27-etm-0-0-8414]). The differences in expression of *MEG3* in asthma with different phenotypes also indicated that *MEG3* might be closely related to the development of the disease, and the further analysis of the relationship between *MEG3* and the course of disease in the research group also proved the same. This also suggested that monitoring of *MEG3* in asthma patients could be used to judge the course of illness or rehabilitation of patients in the future. However, through logistic regression analysis, we found that the course of disease and inflammatory phenotype were independent risk factors for recurrence of asthma, and *MEG3* was an independent protective factor for recurrence of asthma. As the pathological process of asthma, the course of disease and inflammatory phenotype had been recognized unanimously in clinical practice, and the effect of *MEG3* on recurrence of asthma indicated that *MEG3* might be a potential indicator for future treatment of asthma and had extremely high clinical application prospect.

The results of this experiment revealed that *MEG3* was low expressed in asthma patients, while Chen *et al* ([@b28-etm-0-0-8414]) discovered *MEG3* was highly expressed in hepatocytes. The reason for the differences with our results also showed that *MEG3* played different biological effects in different diseases. However, since we have not been able to determine the exact mechanism of action of *MEG3* on asthma through basic experiments, this is the limitation to our research. However, due to the short experimental period, it is impossible to judge the impact of *MEG3* on the long-term prognosis of asthma patients. In the future, we will expand the research period and sample size to obtain more detailed and representative experimental results.

In conclusion, *MEG3* is low expressed in asthma and has good predictive value for it, while its expression is the lowest and course of disease is closely related in mixed granulocytic asthma, which may be the key to the diagnosis and treatment of asthma in the future.
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###### 

Primer sequence.

  Genes     Upstream (5′-3′)        Downstream (5′-3′)
  --------- ----------------------- ------------------------
  *MEG3*    TCGCTCTTCTCCATCGAACCG   GTAGGGCGACGACTTTGAGT
  *GAPDH*   ATGGTGAAGGTCGGTGTGA     CCATGTAGTTGAGGTCAATGAG

###### 

Comparison of general information of patients in the two groups \[n (%)\].

  Characteristics                    Research group (n=119)   Control group (n=125)   t or χ^2^ value   P-value
  ---------------------------------- ------------------------ ----------------------- ----------------- ---------
  Age (years)                          31.5±16.4              32.8±15.8               0.631             0.529
  Course of disease (years)            2.42±0.78                                                        
  BMI (kg/cm^2^)                     22.81±2.18               22.97±2.16              0.576             0.565
  Sex                                                                                 0.186             0.666
    Male                             68 (57.14)               68 (54.40)                                
    Female                           51 (42.86)               57 (45.60)                                
  Smoking                                                                             1.870             0.172
    Yes                              75 (63.03)               68 (54.40)                                
    No                               44 (36.97)               57 (45.60)                                
  Living environment                                                                  0.264             0.608
    Cities and towns                 96 (80.67)               104 (83.20)                               
    Countryside                      23 (19.33)                 21 (16.80)                              
  Family medical history                                                              22.240            \<0.001
    Yes                              35 (29.41)                 8 (6.40)                                
    No                               84 (70.59)               117 (93.60)                               
  History of respiratory disease                                                      13.350            \<0.001
    Yes                              24 (20.17)                 6 (4.80)                                
    No                               95 (79.83)               119 (95.20)                               
  Nationality                                                                         0.462             0.497
    Han                              112 (94.12)              120 (96.00)                               
    Ethnic minorities                  7 (5.88)                 5 (4.00)                                
  Working and learning environment                                                    0.422             0.516
    Outdoor                          79 (66.39)               78 (62.40)                                
    Indoor                           40 (33.61)               47 (37.60)                                
  Inflammatory phenotype                                                                                
    Eosinophilic asthma              49 (41.18)                                                         
    Neutrophilic asthma              32 (26.89)                                                         
    Mixed granulocytic asthma        26 (21.85)                                                         
    Paucigranulocytic asthma         12 (10.08)                                                         

###### 

Univariate analysis

  Characteristics                  Recurrence group (n=42)   Non-recurrence group (n=77)   χ^2^ value   P-value
  -------------------------------- ------------------------- ----------------------------- ------------ ---------
  Age                                                                                        0.483      0.487
    ≤31.5                          24 (57.14)                49 (63.64)                                 
    \>31.5                         18 (42.86)                28 (36.36)                                 
  Course of disease (years)                                                                11.180       \<0.001
    ≤2.42                          15 (35.71)                52 (67.53)                                 
    \>2.42                         27 (64.29)                25 (32.47)                                 
  BMI (kg/cm^2^)                                                                             0.150      0.698
    ≤22.81                         23 (54.76)                45 (58.44)                                 
    \>22.81                        19 (45.24)                32 (41.56)                                 
  Sex                                                                                        0.150      0.698
    Male                           23 (54.76)                45 (58.44)                                 
    Female                         19 (45.24)                32 (41.56)                                 
  Smoking                                                                                  14.340       \<0.001
    Yes                            36 (85.71)                39 (50.65)                                 
    No                               6 (14.29)               38 (49.35)                                 
  Living environment                                                                         0.184      0.668
    Cities and towns               33 (78.57)                63 (81.82)                                 
    Countryside                      9 (21.43)               14 (18.18)                                 
  Family medical history                                                                     0.074      0.785
    Yes                            13 (30.95)                22 (28.57)                                 
    No                             29 (69.05)                55 (71.43)                                 
  History of respiratory disease                                                           30.380       \<0.001
    Yes                            20 (47.62)                4 (5.19)                                   
    No                             22 (52.38)                73 (94.81)                                 
  Nationality                                                                                0.147      0.701
    Han                            40 (95.24)                72 (93.51)                                 
    Ethnic minorities              2 (4.76)                  5 (6.49)                                   
  Working (learning) environment                                                             6.171      0.013
    Outdoor                        34 (80.95)                45 (58.44)                                 
    Indoor                           8 (19.05)               32 (41.56)                                 
  Inflammatory phenotype                                                                     9.698      0.021
    Eosinophilic asthma            16 (38.10)                33 (42.86)                                 
    Neutrophilic asthma            10 (23.81)                22 (28.57)                                 
    Mixed granulocytic asthma      16 (38.10)                10 (12.99)                                 
    Paucigranulocytic asthma       2 (4.76)                  10 (12.99)                                 
  MEG3                                                                                     22.800       \<0.001
    ≤3.48                          35 (83.33)                29 (37.66)                                 
    \>3.48                           7 (16.67)               48 (62.34)                                 

###### 

Assignment table.

  Factors                          Assignment
  -------------------------------- -----------------------------------------------------------------------------------------------------------
  Course of disease                ≤2.42=0; \>2.42=1
  Smoking                          No =0; yes =1
  Living environment               Countryside =0; cities and towns =1
  History of respiratory disease   No =0; yes =1
  Working (learning) environment   Indoor =0; outdoor =1
  Inflammatory phenotype           Paucigranulocytic asthma =0; eosinophilic asthma =1; neutrophilic asthma =2; mixed granulocytic asthma =3
  MEG3                             ≤3.48=0; \>3.48=1

###### 

Results of multivariate analysis.

  Factors                          B       S.E.    Wald      P-value   Exp (B)   95% CI
  -------------------------------- ------- ------- --------- --------- --------- ------------------
  Course of disease                2.543   0.043   12.542    0.012     12.621      12.162--13.425
  Smoking                          0.007   0.785     1.242   0.214       1.241   −0.624--2.572
  Living environment               0.004   0.852     1.026   0.128       1.007   −0.715--2.624
  History of respiratory disease   0.248   0.242     4.162   0.274       1.624     1.124--2.128
  Working (learning) environment   1.358   0.776     5.242   0.324       3.242     1.135--2.165
  Inflammatory phenotype           3.684   0.097   14.684    0.011     35.242      34.162--35.985
  MEG3                             1.492   0.687     4.732   0.030       7.862     1.157--16.527
